
Rebecca Leyland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2543089/publications.pdf Version: 2024-02-01



REBECCALEVIAND

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. Molecular Cancer Therapeutics, 2021, 20, 1723-1734. | 1.9 | 5 |
| 2 | The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology, 2020, 11, 568931. | 2.2 | 100 |
| 3 | MicroRNA-155 is essential for the optimal proliferation and survival of plasmablast B cells. Life Science Alliance, 2019, 2, e201800244. | 1.3 | 17 |
| 4 | Epigenomic Modifications Mediating Antibody Maturation. Frontiers in Immunology, 2018, 9, 355. | 2.2 | 28 |
| 5 | A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist. Clinical Cancer Research, 2017, 23, 3416-3427. | 3.2 | 42 |
| 6 | Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunology Research, 2017, 5, 29-41. | 1.6 | 321 |
| 7 | Abstract 4604: MEDI1873, a GITR ligand fusion protein (GITRL FP), induces effector T-cell proliferation, modulates T-regulatory cell function and has the potential to combine with checkpoint inhibitors. , 2017, , . | | 0 |
| 8 | Abstract 561: MEDI1873: A novel hexameric GITRL fusion protein with potent agonsitic and immunomodulatory activities in preclinical systems. , 2016, , . | | 1 |
| 9 | Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget, 2016, 7, 68278-68291. | 0.8 | 48 |
| 10 | Abstract 4902: A mouse GITRL fusion protein drives T-cell activation and antitumor activity in preclinical mouse models of cancer. , 2016, , . | | 0 |
| 11 | Abstract 4186: Syngenomic fingerprint: the biomic characterization of the mouse syngeneic tumor models. , 2016, , . | | 0 |
| 12 | A mouse GITRI fusion protein drives T cell activation and antitumor activity in preclinical mouse models of cancer. , 2015, 3, . | | 0 |
| 13 | MicroRNA-155 controls affinity-based selection by protecting c-MYC+ B cells from apoptosis. Journal of Clinical Investigation, 2015, 126, 377-388. | 3.9 | 41 |
| 14 | The miR-155–PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation. Journal of Experimental Medicine, 2014, 211, 2183-2198. | 4.2 | 83 |
| 15 | miRâ€155: an ancient regulator of the immune system. Immunological Reviews, 2013, 253, 146-157. | 2.8 | 286 |
| 16 | MicroRNA-155 Is Required for <i>Mycobacterium bovis</i> BCG-Mediated Apoptosis of Macrophages. Molecular and Cellular Biology, 2012, 32, 2239-2253. | 1.1 | 126 |
| 17 | Characterisation of 5â€HT _{3C} , 5â€HT _{3D} and 5â€HT _{3E} receptor subunits: evolution, distribution and function. Journal of Neurochemistry, 2009, 108, 384-396. | 2.1 | 88 |